At the institute's 42nd convocation ceremony, Union Minister described its eight-institution MoU initiative as a unique collaborative effort that brings together premier national institutions to create a synergistic research ecosystem
The 38% adjusted EBITDA margin of base business has been supported by robust growth in the CDMO segment
The move signals a strategic pivot toward deeper integration between clinical leadership and medical technology developers
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Global specialty pipeline accelerates growth
Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support
Highlighting KEYTRUDA & expanding cancer pipeline
Subscribe To Our Newsletter & Stay Updated
